DBV Technologies Stock Drops Over 2% and Breaks Its Support at €2.75
The French biotech company falls during the session, going against the grain of a significantly bullish SBF 120. The stock slips to the bottom of the broad index's ranking, after briefly regaining some ground the previous day. Declared short positions remain substantial as the company prepares a key regulatory filing in the United States this fall.
The Stock Breaks Its Support at €2.75 and Dips Below Its Three Moving Averages
DBV Technologies stock loses 2.21% to €2.74 by midday, while the SBF 120 advances by 0.73%. The stock has broken its support at €2.75 during the session, a threshold that was first breached at the end of June and has been tested several times since. This break is particularly significant as the price now significantly trails its three moving averages, with a gap of -4.60% from the MM20 (€2.87), -13.35% from the MM50 (€3.16), and -11.39% from the MM200 (€3.09). The RSI at 41 remains in the neutral zone but is weakening, while the MACD, having just turned positive, sends a still fragile signal. Over the past month, the stock has lost 15.4%, erasing part of its annual gains which remain positive at over 75%. The cumulative net short position reaches 3.36% of the capital, driven by three funds according to reviewed declarations. This level has increased by 0.55 points over thirty days, after 2.81% a month ago. This contained but rising selling pressure reflects a still cautious institutional positioning on the stock, without drawing a definitive conclusion on the stock's trajectory.
A Regulatory Filing in the United States Expected in the Third Quarter of 2026
The biotech company based in Châtillon (Hauts-de-Seine), led by Michel de Rosen, announced on June 29 that it had finalized discussions with the Food and Drug Administration regarding the submission of a biological license application for its Viaskin Peanut patch, intended for children aged 4 to 7 years with peanut allergies. The company aims to submit the application in the third quarter of 2026, provided that no additional requests are made by the American agency. This step represents a central milestone for a product that has been in development for over a decade. DBV Technologies has been listed in Paris and on the Nasdaq via ADS since 2014, with a ratio of one ADS for every five ordinary shares since the end of November 2024. Paris remains the most liquid market for the stock. The breach of the €2.75 support during the session becomes the technical reference to monitor over the next few sessions, as this level has served as a contact zone several times since June.
